IRIS

2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209)

CASRN 1163-19-5

Health Hazard Assessments for Effects Other than Cancer

Reference Dose for Oral Exposure (RfD) (PDF) (25 pp, 232 K) last updated: 06/30/2008

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Nervous 7 x 10-3 Neurobehavioral effects NOAEL : 2.22
mg/kg-day
300 Low

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (25 pp, 232 K) last updated: 06/30/2008
Information reviewed but value not estimated.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (25 pp, 232 K) last updated: 06/30/2008

WOE Characterization Framework for WOE Characterization
Suggestive evidence of carcinogenic potential Guidelines for Carcinogen Risk Assessment (US EPA, 2005)
Basis:
  • Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for decabromodiphenyl ether provides suggestive evidence of carcinogenic potential.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (25 pp, 232 K)

Oral Slope Factor: 7 x10 -4 per mg/kg-day
Drinking Water Unit Risk: 2 x10 -8 per µg/L
Extrapolation Method: Multistage model with linear extrapolation from the point of departure (LED12).
Tumor site(s): Hepatic
Tumor type(s): Liver neoplastic nodules or carcinoma (combined) (NTP (1986))



Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (25 pp, 232 K)

Not Assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.